Retatrutide activates GLP-1, GIP, and glucagon receptors, making it a triple agonist and the most receptor-diverse obesity compound currently in clinical development
PMID: 28642676
Accelerated eryptosis might be associated with anemia due to rapid clearance of eryptotic cells via efferocytosis, activation of blood clotting, and damage to endothelial cells caused by adherence of eryptotic cells to them (Fig
The absence of a canonical receptor has complicated traditional drug development approaches, which often rely on receptor binding and structureactivity optimization
Archived from the original on December 20, 2016
Potential references were identified through an extensive search of PubMed for articles published between January 1, 2000, and January 1, 2025